Clinical trials: Pregnancy Hemorrhage, open to volunteers
Abnormal Uterine Bleeding Due to Adenomyosis (Disorder)
Radiofrequency Endometrial Ablation or Uterine Artery Embolization for Treatment of Adenomyosis-related Abnormal Uterine Bleeding
The present study aims to compare the efficacy (menstrual blood loss, pain, quality of life) and the safety (complications, recovery) of each conservative intervention (RFA, UAE) versus hysterectomy for the treatment of…
- Trial name
- ADENOTREAT (NCT07195305)
- Testing
- Radiofrequency endometrial ablation, Uterine artery embolization, Hysterectomy
- Where
- 4 sites in France
- Volunteers
- 230 people
- Sponsor
- University Hospital, Bordeaux
Gynaecological Cancers, Ovarian Cancer
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
The goal of the MYSSELF (Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers) study is to investigate which biological markers (i.e., (epi)genetic biomarkers) found in…
- Conditions
- Gynaecological Cancers, Ovarian Cancer, Endometrial Cancer, Vulvar Cancer
- Trial name
- MYSSELF (NCT07902375)
- Testing
- Colli-Pee 20 mL device with UCM, Evalyn Brush
- Where
- Belgium
- Volunteers
- 730 people
- Sponsor
- Universiteit Antwerpen
Hemorrhage, Obstetric, Uterine Abnormality
Evaluation of the Non-inferiority of Resorbable Gelatin Embolization Compared to Embolization Combined With Endometrial Aspiration for the Management of Hemorrhagic Uterine Vascular Abnormalities Following Premature Termination of Pregnancy
The goal of this clinical trial is to determine the best treatment for patients who experience vaginal bleeding following a premature termination of pregnancy.
- Conditions
- Hemorrhage, Obstetric, Uterine Abnormality, Uterine Artery Embolization, Vaginal Bleeding During Pregnancy
- Trial name
- NIEMBUT (NCT07206342)
- Testing
- embolization therapy, embolization followed by aspiration
- Where
- 4 sites in France
- Volunteers
- 110 people
- Sponsor
- University Hospital, Grenoble
Placenta Accreta Spectrum
Effectiveness of REBOA in Reducing Blood Loss During Cesarean Section in Patients with PAS
Obstetric hemorrhage is one of the leading causes of maternal mortality and morbidity worldwide. The major risk factors for obstetric hemorrhage include placenta previa and placenta accreta spectrum (PAS) disorders.
- Trial name
- NCT06721182
- Testing
- REBOA
- Volunteers
- 100 people
- Sponsor
- Nazarbayev University
Abnormal Uterine Bleeding (AUB)
Pipelle Versus Manual Vacuum Aspiration Cannula for Endometrial Biopsy in Women With Abnormal Uterine Bleeding
women globally, often requiring endometrial tissue sampling for accurate evaluation and diagnosis. Traditional office-based sampling techniques like Pipelle are widely used, but the disposable instruments can be relatively…
- Trial name
- NCT07731581
- Testing
- Manual Vacuum Aspiration (MVA) Cannula, Pipelle Endometrial Suction Curette
- Volunteers
- 80 people
- Sponsor
- University of Health Sciences Lahore
Urologic Diseases, Hematuria
A Study of Ward Admissions for Haematuria
This multicenter, prospective observational study will evaluate national and international practice variations (if present) in the emergency management of patients admitted to hospital with haematuria, inform a consensus…
- Conditions
- Urologic Diseases, Hematuria, Hematuria; Benign, Bladder Cancer
- Trial name
- WASHOUT (NCT07395037)
- Testing
- Inpatient work-up and management
- Where
- United Kingdom
- Volunteers
- 1,050 people
- Sponsor
- British Urology Researchers in Surgical Training
Anemia, Iron Deficiency, Uterine Bleeding
IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department
The primary aim of this randomized trial is to assess the efficacy of IV Ferric Derisomaltose vs Oral Iron in the management of women with severe Iron Deficiency Anemia due to Uterine Bleeding in the emergency department.
- Trial name
- NCT05304442
- Testing
- Ferric Derisomaltose 1000 Mg in 10 mL INTRAVENOUS SOLUTION [Monoferric], Ferrous Sulfate 65 mg elemental iron (325 mg tablets)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Baylor College of Medicine
Abnormal Uterine Bleeding, Endometriosis
Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy
The aim of this study is to show the superiority of the new unidirectional barbed suture (SYMMCORA® mid-term, unidirectional) to conventional suture material in terms of time to perform the vaginal cuff closure during gynecologic…
- Conditions
- Abnormal Uterine Bleeding, Endometriosis, Uterine Prolapse, Uterine Cancer
- Trial name
- BARHYSTER (NCT06024109)
- Testing
- Closure of the Vaginal Cuff after Total Hysterectomy
- Where
- 2 sites in Germany, Spain
- Volunteers
- 132 people
- Sponsor
- Aesculap AG
Hematuria
Study on Risk Assessment for Patients With Microscopic Hematuria (Non-Visible Blood in Urine) Using a Urine Marker Test
The goal of this clinical study is to learn how well a urine test called Xpert® Bladder Cancer Detect (Xpert BC-D) can help doctors assess the risk of bladder cancer in people with non-visible blood in their urine (microscopic…
- Trial name
- UroDetect III (NCT07307300)
- Where
- Germany
- Volunteers
- 1,475 people
- Sponsor
- Christian Bolenz
IUD, Abnormal Uterine Bleeding
Assessing Pain and Effectiveness of Carevix Device for IUD Insertions
The goal of this clinical trial is to evaluate patient-reported pain, bleeding, and device efficiency along with provider satisfaction and ease of use between IUD insertions using a suction cervical stabilizer (new device, FDA…
- Conditions
- IUD, Abnormal Uterine Bleeding, Pain, Cervical
- Trial name
- CARE (NCT07290517)
- Testing
- Carevix, Tenaculum
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Indiana University
Heavy Menstrual Bleeding
Delivering tAN to Reduce HMB: The LUNA Study
The LUNA study is a prospective, randomized, double-blind, sham-controlled, decentralized clinical trial in participants with heavy menstrual bleeding of no known structural cause.
- Trial name
- LUNA (NCT07326722)
- Testing
- Sparrow Link
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Spark Biomedical, Inc.
Post Partum Haemorrhage
Outcomes and Perceptions of the Implementation of the JADA Device in a Stage II Postpartum Hemorrhage Management Protocol in Referral Hospitals of the Colombian Pacific Region
This study focuses on postpartum hemorrhage (PPH), a condition that stands out as the leading cause of global maternal mortality. Annually, about 14 million women experience PPH, resulting in approximately 70,000 deaths.
- Trial name
- JADAValle (NCT06843265)
- Testing
- Vacuum- Induce Hemorrhage Control
- Volunteers
- 24 people
- Sponsor
- Fundacion Clinica Valle del Lili
Postpartum Hemorrhage, Uterine Atony
Exteriorization Versus In Situ Hysterotomy Repair During Cesarean: Effects on Uterine Tone
During standard cesarean deliveries, there are two ways that obstetricians repair the incision on the uterus (hysterotomy after delivery of the baby.
- Conditions
- Postpartum Hemorrhage, Uterine Atony, Uterine Atony With Hemorrhage, Cesarean Section
- Trial name
- NCT07606846
- Testing
- Test Intervention: In Situ Repair, Comparator Intervention: Exteriorization
- Volunteers
- 60 people
- Sponsor
- Stanford University
Menorrhagia, Uterine Fibroids
to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia
The goal of this clinical trial was to determine whether the investigational drug KLH-2109 is effective for treating excessive menstrual bleeding in patients with uterine fibroids.
- Trial name
- NCT07378098
- Where
- South Korea
- Volunteers
- 254 people
- Sponsor
- JW Pharmaceutical
Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs)
Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China
The goal of this observational study is to validate the EQ-5D-Y-3L and EQ-5D-Y-5L in measuring health-related quality of life (HRQoL) for paediatric patients with different health conditions in China.
- Conditions
- Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs), Pneumonia Childhood, Neuroblastoma (NB)
- Trial name
- NCT06873672
- Where
- China
- Volunteers
- 360 people
- Sponsor
- RenJi Hospital
Third Stage of Delivery
Maternal Outcomes Following Manual Lysis of the Placenta.
Comparison of maternal outcomes following manual lysis of placenta 15 vs 30 minutes after delivery. A primary outcome of the drop in hemoglobin will be compared between the two groups.
- Trial name
- NCT03626844
- Testing
- Manual Lysis of Placenta after 15 minutes (Intervention), Manual Lysis of Placenta after 30 minutes (Control)
- Where
- Israel
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Holy Family Hospital, Nazareth, Israel
Hemophilia A, Hemophilia A, Severe
Hemophilia A Research Program
This study longitudinally observes the intergenerational (mother-child) continuum in hemophilia A from pregnancy through early childhood.
- Conditions
- Hemophilia A, Hemophilia A, Severe, Factor VIII (FVIII), FVIII Deficiency
- Trial name
- HARP (NCT07414511)
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Washington
Placenta Previa
Tranexamic Acid vs Vasopressin in Placenta Previa Trial
Placenta previa is a major obstetric condition associated with increased risk of excessive blood loss during cesarean section, leading to maternal morbidity and mortality.
- Trial name
- TXA-VASO-PP (NCT07423156)
- Testing
- Group A: Tranexamic acid, Group B: Vasopressin
- Where
- Pakistan
- Volunteers
- 58 people
- Sponsor
- Allama Iqbal Medical College
Liver Cirrhosis
Faecal Microbiota Transplantation for Liver Cirrhosis
The purpose is to investigate the effect of faecal microbiota transplantation (FMT) on complications, progression, and mortality of patients with liver cirrhosis.
- Trial name
- CHiFT (NCT04932577)
- Testing
- Faecal microbiota transplantation
- Where
- Denmark
- Volunteers
- 220 people
- Sponsor
- University of Aarhus
Placenta Previa, Placenta Accreta Spectrum
Planned Delivery at 37 Versus 36 Weeks in Pregnancies With Placenta Previaand Accreta
Current clinical practice guidelines recommend planned cesarean delivery(CD) at 34-37 weeks of gestation in pregnant women with placenta previa and accreta.
- Conditions
- Placenta Previa, Placenta Accreta Spectrum, Antepartum Bleeding, Emergency Cesarean Section
- Trial name
- NCT07025954
- Testing
- Cesarean delivery
- Where
- 6 sites in China
- Volunteers
- 600 people
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University